We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Junshi Completes Enrollment for Phase 1 Trial of COVID-19 Antibody
Junshi Completes Enrollment for Phase 1 Trial of COVID-19 Antibody
Shanghai-based Junshi Biosciences announced that it has finished enrolling participants in a phase 1 trial of JS016, its COVID-19 neutralizing antibody.